Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.47 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.45 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | SMO | Q99835 | 1/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.37 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.37 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.37 |
| ▸ | BTK | Q06187 | 1/20 | 0.37 |
| ▸ | MRGPRX2 | Q96LB1 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15509175 | 0.78 | DYRK1A (0.45) | DYRK1APTPN11HRH4HDAC6MAP4K4 | |
| SCHEMBL16991350 | 0.78 | DYRK1A (0.45) | DYRK1APTPN11HRH4HDAC6MAP4K4 | |
| SCHEMBL28219641 | 0.77 | MAP4K4 (0.47) | DYRK1APTPN11HRH4HDAC6MAP4K4 | |
| SCHEMBL1927645 | 0.75 | HDAC6 (0.49) | DYRK1APTPN11HRH4HDAC6MAP4K4 | |
| SCHEMBL27379604 | 0.74 | HRH4 (0.38) | DYRK1APTPN11HRH4HDAC6MAP4K4 | |
| SCHEMBL13806026 | 0.74 | DYRK1A (0.55) | DYRK1AHRH4MAP4K4HRH3MAPK8 | |
| SCHEMBL13806029 | 0.74 | DYRK1A (0.55) | DYRK1AHRH4MAP4K4HRH3MAPK8 | |
| SCHEMBL17262265 | 0.74 | PTPN11 (0.45) | DYRK1APTPN11HRH4HDAC6MAP4K4 | |
| SCHEMBL19205970 | 0.74 | PTPN11 (0.45) | DYRK1APTPN11HRH4HDAC6MAP4K4 | |
| SCHEMBL5562201 | 0.74 | POLB (0.51) | SMOHCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9878987-B2 | HSP70 modulators and methods for making and using the same | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2018-01-30 | — | — | US | disclosed |
| US-20170233352-A1 | HSP70 MODULATORS AND METHODS FOR MAKING AND USING THE SAME | MEMORIAL SLOAN KETTERING CANCER CENTER | 2017-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170233352-A1 | HSP70 MODULATORS AND METHODS FOR MAKING AND USING THE SAME | HSPA2, HSP90AA1, HSP90AB1 | DYRK1A 2598/4885PTPN11 3909/4885HRH4 2969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.